ProMetic presents preclinical data for prostate and pancreatic cancer at the AA...(pharmaceutical products the availability...)

Date:4/17/2008

pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
7. Prometic to present at the American Chemical Society
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health